alg Andre negative prognostiske faktorer (alder > 40 år, hankøn, bridging fibrose) bør tages i betragtning ved fortsat behandling til 12 måneder.
Treatment should be continued for another 6-month period (i. e., a total of 12 months) in patients who exhibit negative HCV-RNA at month 6, and with viral genotype 1 (as determined in a pre-treatment sample) and high pre-treatment viral load. i dic